Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q3

3341.TEDINET S100SVMG
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥254.1bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥232.8bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥6.5bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥7.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥3.8bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥3.8bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥194.4bnat 2023-12-31Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥187.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥134.9bnat 2023-12-31Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥59.5bnat 2023-12-31Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥56.3bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥16.9bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥125.992023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.552023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥143.232022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥5.4bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥225.6bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥225.6bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥10.6bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥7.4bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥7.3bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥35m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥795m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥31.2bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥21.2bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥9.9bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥555m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥264.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥254.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥10.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥12.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥4.9bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2m
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥10.6bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥602m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥29.3bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥18.9bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10.4bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥456m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥243.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥232.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥10.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥10.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 356
ItemContextValueUnit
Income taxes deferredPrior1YTDDuration950000000JPY
Income taxes deferredCurrentYTDDuration851000000JPY
Income taxesPrior1YTDDuration2671000000JPY
Income taxesCurrentYTDDuration2699000000JPY
Profit lossPrior1YTDDuration4289000000JPY
Profit lossCurrentYTDDuration3769000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration4289000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration3769000000JPY
Profit lossPrior1YTDDuration4289000000JPY
Profit lossCurrentYTDDuration3769000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration10000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration4000000JPY
Other comprehensive incomePrior1YTDDuration10000000JPY
Other comprehensive incomeCurrentYTDDuration4000000JPY
Comprehensive incomePrior1YTDDuration4300000000JPY
Comprehensive incomeCurrentYTDDuration3773000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration4300000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration3773000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember208074000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember18870000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember5899000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember232844000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration232844000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember2000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember10446000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember10000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember10459000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-10459000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember208076000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember29316000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember5909000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember243303000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-10459000000JPY
Net salesPrior1YTDDuration232844000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember10601000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember-456000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember602000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember10747000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-4918000000JPY
Operating incomePrior1YTDDuration5829000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember225570000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember21222000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember7334000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember254127000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration254127000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember9940000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass